Jan 182023

Korean Biotechs Share Their Insights With Sidley At J.P. Morgan Healthcare Conference 2023

Josh Hofheimer
,

Josh Hofheimer reports the takeaways from Sidley’s co-hosted pitch day with KoreaBio and BioCentury at the J.P. Morgan Healthcare Conference. The session included key insights on entrepreneurial developments and an investor panel on macroeconomic challenges.

Korean Biotechs Share Their Insights With Sidley at J.P. Morgan Healthcare Conference 2023 from Sidley Austin LLP on Vimeo.

From left to right: Taejin Yoon, Dan Wang, Joshua Hofheimer.

This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.

Josh Hofheimer

jhofheimer@sidley.com

You might also like
Hong Kong’s Biotech Listings Emerge From Two-Year Downturn With 18As Booming

Biotech and medtech startups based in the People’s Republic of China (P.R.C.) are flocking to Hong Kong to float. Meng Ding explains how a combination of listing reforms and an explosion of innovation in the Greater Bay Area have led to Hong Kong’s 18A process being popular for life sciences.

New Guidance on Parallel Import Licensing Applicable to Northern Ireland Under the Windsor Framework

Brexit brought new challenges to the pharmaceutical industry, one of them being the special situation of Northern Ireland (NI), which, although part of the UK, remained subject to EU law under the NI Protocol. Pharmaceutical products placed on the NI market had to comply with EU law. For import purposes this created de facto an EU border between NI and the rest of the UK (namely England, Wales, and Scotland). The Windsor Framework provides a new set of arrangements to restore the smooth flow of trade within the UK.

Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs

Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance.